The first experience in using abiraterone acetate in patients with castration-refractory prostate cancer
Even in the mid-twentieth century, Huggins and Hodges proved the susceptibility of prostate cancer cells to hormonal manipulations, by using surgical castration as an example. An average of 18–36 months after initiation of first-line hormonal therapy, patients develop the castration resistance in pr...
Main Authors: | L. M. Rapoport, E. A. Bezrukov, A. V. Kondrashina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-11-01
|
Series: | Андрология и генитальная хирургия |
Subjects: | |
Online Access: | https://agx.abvpress.ru/jour/article/view/154 |
Similar Items
-
A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01) -
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01) -
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01) -
Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01) -
Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)